BG107806A - Състав, включващ камптотецинови и стилбенови производни, за лечение на рак - Google Patents
Състав, включващ камптотецинови и стилбенови производни, за лечение на рак Download PDFInfo
- Publication number
- BG107806A BG107806A BG107806A BG10780603A BG107806A BG 107806 A BG107806 A BG 107806A BG 107806 A BG107806 A BG 107806A BG 10780603 A BG10780603 A BG 10780603A BG 107806 A BG107806 A BG 107806A
- Authority
- BG
- Bulgaria
- Prior art keywords
- combretastatin
- cpt
- combination
- treatment
- camptothecin
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 30
- 238000011282 treatment Methods 0.000 title claims abstract description 20
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical class C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 title claims abstract description 13
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 title abstract description 18
- 229940127093 camptothecin Drugs 0.000 title abstract description 11
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 title abstract description 10
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 title abstract description 10
- 201000011510 cancer Diseases 0.000 title description 9
- LGZKGOGODCLQHG-CYBMUJFWSA-N 5-[(2r)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol Chemical group C1=C(O)C(OC)=CC=C1C[C@@H](O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-CYBMUJFWSA-N 0.000 claims description 58
- LGZKGOGODCLQHG-UHFFFAOYSA-N combretastatin Natural products C1=C(O)C(OC)=CC=C1CC(O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-UHFFFAOYSA-N 0.000 claims description 55
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 50
- 238000000034 method Methods 0.000 claims description 11
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 230000002195 synergetic effect Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 15
- 239000002246 antineoplastic agent Substances 0.000 description 13
- 231100000252 nontoxic Toxicity 0.000 description 11
- 230000003000 nontoxic effect Effects 0.000 description 11
- 206010009944 Colon cancer Diseases 0.000 description 9
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- -1 combretastatin Chemical class 0.000 description 7
- 230000034994 death Effects 0.000 description 7
- 231100000517 death Toxicity 0.000 description 7
- 239000000825 pharmaceutical preparation Substances 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- HVXBOLULGPECHP-WAYWQWQTSA-N Combretastatin A4 Chemical compound C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 229960005537 combretastatin A-4 Drugs 0.000 description 3
- HVXBOLULGPECHP-UHFFFAOYSA-N combretastatin A4 Natural products C1=C(O)C(OC)=CC=C1C=CC1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 201000010897 colon adenocarcinoma Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000003327 cancerostatic effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 150000004814 combretastatins Chemical class 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 239000011363 dried mixture Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24343100P | 2000-10-27 | 2000-10-27 | |
| US24558200P | 2000-11-06 | 2000-11-06 | |
| US25013800P | 2000-12-01 | 2000-12-01 | |
| PCT/EP2001/012985 WO2002034244A2 (en) | 2000-10-27 | 2001-10-25 | A combination comprising camptothecin and a stilbene derivative for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG107806A true BG107806A (bg) | 2004-06-30 |
Family
ID=27399663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG107806A BG107806A (bg) | 2000-10-27 | 2003-05-12 | Състав, включващ камптотецинови и стилбенови производни, за лечение на рак |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6562834B2 (et) |
| EP (1) | EP1333820A2 (et) |
| JP (1) | JP2004517821A (et) |
| KR (1) | KR100742524B1 (et) |
| CN (1) | CN1200712C (et) |
| AU (2) | AU1602902A (et) |
| BG (1) | BG107806A (et) |
| BR (1) | BR0114856A (et) |
| CA (1) | CA2426898A1 (et) |
| EA (1) | EA005400B1 (et) |
| EE (1) | EE200300184A (et) |
| HR (1) | HRP20030382A2 (et) |
| HU (1) | HUP0302629A3 (et) |
| IL (1) | IL155509A0 (et) |
| MX (1) | MXPA03002882A (et) |
| NO (1) | NO324844B1 (et) |
| NZ (1) | NZ524855A (et) |
| PL (1) | PL365685A1 (et) |
| SK (1) | SK5122003A3 (et) |
| WO (1) | WO2002034244A2 (et) |
| YU (1) | YU29803A (et) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020183266A1 (en) * | 2001-03-15 | 2002-12-05 | Aventis Pharma, S.A. | Combination comprising combretastatin and anticancer agents |
| CA2383259A1 (en) | 2002-04-23 | 2003-10-23 | Celator Technologies Inc. | Synergistic compositions |
| US20080075762A1 (en) * | 2001-10-03 | 2008-03-27 | Paul Tardi | Compositions for delivery of drug combinations |
| US7850990B2 (en) * | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| CN101085743B (zh) * | 2006-06-06 | 2012-02-15 | 浙江大德药业集团有限公司 | 含氟烷氧基康普立停衍生物及制法和用途 |
| TW200819409A (en) * | 2006-10-19 | 2008-05-01 | Univ Taipei Medical | Z-stilbenes derivatives and the pharmaceutical composition thereof |
| CN103764604B (zh) | 2011-01-28 | 2017-02-08 | 肯塔基大学研究基金会 | 茋类似物和治疗癌症的方法 |
| JP2014527036A (ja) | 2011-06-27 | 2014-10-09 | ザ ジャクソン ラボラトリー | 癌および自己免疫疾患の処置のための方法および組成物 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399276A (en) | 1981-01-09 | 1983-08-16 | Kabushiki Kaisha Yakult Honsha | 7-Substituted camptothecin derivatives |
| JPS57116015A (en) | 1981-01-09 | 1982-07-19 | Yakult Honsha Co Ltd | Antitumor agent |
| JPS57116074A (en) | 1981-01-09 | 1982-07-19 | Yakult Honsha Co Ltd | Novel camptothecin derivative and its preparation |
| US4473692A (en) | 1981-09-04 | 1984-09-25 | Kabushiki Kaisha Yakult Honsha | Camptothecin derivatives and process for preparing same |
| JPS58154582A (ja) | 1982-03-10 | 1983-09-14 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体およびその製造法 |
| JPS595188A (ja) | 1982-06-30 | 1984-01-12 | Yakult Honsha Co Ltd | １０−ヒドロキシカンプトテシンの製造法 |
| JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
| US4981968A (en) | 1987-03-31 | 1991-01-01 | Research Triangle Institute | Synthesis of camptothecin and analogs thereof |
| CA1332413C (en) | 1987-06-25 | 1994-10-11 | Kabushiki Kaisha Yakult Honsha | Camptothecin derivatives and process for preparing same |
| US5004758A (en) | 1987-12-01 | 1991-04-02 | Smithkline Beecham Corporation | Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells |
| JPH0615547B2 (ja) | 1988-01-20 | 1994-03-02 | 株式会社ヤクルト本社 | 新規なカンプトテシン誘導体 |
| JP2524803B2 (ja) | 1988-03-29 | 1996-08-14 | 株式会社ヤクルト本社 | 新規なカンプトテシン誘導体およびその製造法 |
| JP2524804B2 (ja) | 1988-03-29 | 1996-08-14 | 株式会社ヤクルト本社 | 新規なカンプトテシン誘導体及びその製造法 |
| EP0540099B1 (en) | 1991-10-29 | 1996-04-17 | Glaxo Wellcome Inc. | Water soluble camptothecin derivatives |
| TW325458B (en) | 1993-09-08 | 1998-01-21 | Ajinomoto Kk | Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer |
| TW334418B (en) | 1995-03-07 | 1998-06-21 | Ajinomoto Kk | Stilbene derivatives and pharmaceutical compositions |
| US6504029B1 (en) | 1995-04-10 | 2003-01-07 | Daiichi Pharmaceutical Co., Ltd. | Condensed-hexacyclic compounds and a process therefor |
| GB9510716D0 (en) | 1995-05-26 | 1995-07-19 | Pharmacia Spa | Substituted camptothecin derivatives and process for their preparation |
| US5670500A (en) | 1995-05-31 | 1997-09-23 | Smithkline Beecham Corporation | Water soluble camptothecin analogs |
| US5663177A (en) | 1995-05-31 | 1997-09-02 | Smithkline Beecham Corporation | Water soluble camptothecin analogs |
| ATE224900T1 (de) | 1995-06-21 | 2002-10-15 | Sod Conseils Rech Applic | Camptothecinanaloge, verfahren zur ihrer herstellung, ihre verwendungals arzneimittel und diese enthaltende pharmazeutische zusammenfassungen |
| JP3054669B2 (ja) | 1995-10-16 | 2000-06-19 | 余川商事株式会社 | 積雪落下防止装置 |
| JPH11296051A (ja) | 1998-04-08 | 1999-10-29 | Canon Inc | プロセスカートリッジ |
| AU773420B2 (en) * | 1998-12-11 | 2004-05-27 | Medarex, Inc. | Prodrug compounds and process for preparation thereof |
| GB9903404D0 (en) * | 1999-02-16 | 1999-04-07 | Angiogene Pharm Ltd | Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis |
| CA2432792C (en) | 2000-12-22 | 2012-04-03 | Bristol-Myers Squibb Company | Methods for modulating tumor growth and metastasis |
-
2001
- 2001-10-25 SK SK512-2003A patent/SK5122003A3/sk not_active Application Discontinuation
- 2001-10-25 JP JP2002537298A patent/JP2004517821A/ja active Pending
- 2001-10-25 CA CA002426898A patent/CA2426898A1/en not_active Abandoned
- 2001-10-25 NZ NZ524855A patent/NZ524855A/en unknown
- 2001-10-25 EA EA200300516A patent/EA005400B1/ru not_active IP Right Cessation
- 2001-10-25 YU YU29803A patent/YU29803A/sh unknown
- 2001-10-25 AU AU1602902A patent/AU1602902A/xx active Pending
- 2001-10-25 IL IL15550901A patent/IL155509A0/xx unknown
- 2001-10-25 AU AU2002216029A patent/AU2002216029B2/en not_active Ceased
- 2001-10-25 HU HU0302629A patent/HUP0302629A3/hu unknown
- 2001-10-25 WO PCT/EP2001/012985 patent/WO2002034244A2/en not_active Ceased
- 2001-10-25 CN CNB018179800A patent/CN1200712C/zh not_active Expired - Fee Related
- 2001-10-25 EP EP01988584A patent/EP1333820A2/en not_active Withdrawn
- 2001-10-25 KR KR1020037005754A patent/KR100742524B1/ko not_active Expired - Fee Related
- 2001-10-25 BR BR0114856-7A patent/BR0114856A/pt not_active IP Right Cessation
- 2001-10-25 MX MXPA03002882A patent/MXPA03002882A/es not_active Application Discontinuation
- 2001-10-25 PL PL01365685A patent/PL365685A1/xx not_active Application Discontinuation
- 2001-10-25 EE EEP200300184A patent/EE200300184A/et unknown
- 2001-10-25 HR HR20030382A patent/HRP20030382A2/hr not_active Application Discontinuation
- 2001-10-26 US US09/984,043 patent/US6562834B2/en not_active Expired - Fee Related
-
2003
- 2003-04-10 NO NO20031656A patent/NO324844B1/no unknown
- 2003-05-12 BG BG107806A patent/BG107806A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ524855A (en) | 2004-10-29 |
| HUP0302629A2 (hu) | 2003-11-28 |
| EA200300516A1 (ru) | 2003-08-28 |
| HRP20030382A2 (en) | 2005-04-30 |
| EE200300184A (et) | 2003-08-15 |
| NO324844B1 (no) | 2007-12-17 |
| KR100742524B1 (ko) | 2007-08-02 |
| US6562834B2 (en) | 2003-05-13 |
| YU29803A (sh) | 2006-05-25 |
| CN1471396A (zh) | 2004-01-28 |
| AU1602902A (en) | 2002-05-06 |
| EA005400B1 (ru) | 2005-02-24 |
| CA2426898A1 (en) | 2002-05-02 |
| WO2002034244A2 (en) | 2002-05-02 |
| JP2004517821A (ja) | 2004-06-17 |
| MXPA03002882A (es) | 2004-12-03 |
| AU2002216029B2 (en) | 2006-01-05 |
| NO20031656L (no) | 2003-04-10 |
| SK5122003A3 (en) | 2003-12-02 |
| HK1058623A1 (en) | 2004-05-28 |
| CN1200712C (zh) | 2005-05-11 |
| BR0114856A (pt) | 2004-06-15 |
| US20020115677A1 (en) | 2002-08-22 |
| IL155509A0 (en) | 2003-11-23 |
| KR20030082544A (ko) | 2003-10-22 |
| NO20031656D0 (no) | 2003-04-10 |
| WO2002034244A3 (en) | 2003-05-30 |
| PL365685A1 (en) | 2005-01-10 |
| HUP0302629A3 (en) | 2005-05-30 |
| EP1333820A2 (en) | 2003-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6214860B1 (en) | Synergistic antitumor composition containing a naphthalensulphonic acid derivative | |
| EP3359255A2 (en) | Combination therapies for treating cancer | |
| CZ302451B6 (cs) | Protirakovinová farmaceutická kombinace | |
| US20120208883A1 (en) | Treatment of oncological diseases | |
| AU2005294432A1 (en) | Use of nordihydroguaiaretic acid derivatives in the treatment of drug resistant cancer, viral and microbial infection | |
| US6562834B2 (en) | Combination comprising camptothecin and a stilbene derivative for the treatment of cancer | |
| JP2706371B2 (ja) | 癌治療用補助剤及びそれを用いたキット | |
| AU2002216029A1 (en) | A combination comprising camptothecin and a stilbene derivative for the treatment of cancer | |
| RU2396952C2 (ru) | Комбинация, включающая комбретастатин и противораковые средства | |
| US6548488B2 (en) | Composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer | |
| US20030195161A1 (en) | Composition comprising camptothecin or a camptothecin derivative and a topoisomerase II inhibitor for the treatment of cancer | |
| ZA200302552B (en) | A combination comprising camptothecin and a stilbene derivative for the treatment of cancer. | |
| HK1058623B (en) | A combination comprising camptothecin and a stilbene derivative for the treatment of cancer | |
| KR20010102402A (ko) | 상승작용성 항종양 조성물 | |
| EP1716852A1 (en) | A composition comprising campothecin or a campothecin derivative and an alkylating agent for the treatment of cancer | |
| HK1128234B (en) | Combination comprising combretastatin and anticancer agents |